Genitourinary Cancers

Genitourinary Cancers

Intermediate-risk prostate cancer patients managed with surveillance had worse outcomes compared with low-risk prostate cancer patients managed with surveillance.

High-dose radiation therapy did not improve overall survival compared with the standard dose in stage II localized prostate cancer, but did show some benefits.

A large retrospective analysis suggests the number of patients diagnosed with intermediate- and high-risk prostate cancer has increased since 2011.

Patients with a history of testicular cancer had a fivefold higher risk of developing aggressive prostate cancer when compared with those with no history of testicular cancer.

Levels of AR-V7 in metastatic castration-resistant prostate cancer patients could guide physicians to treat with either taxanes or enzalutamide/abiraterone.

An 8-year analysis confirmed that adding radiotherapy to androgen deprivation therapy in prostate cancer improved patient overall survival by more than a year.

This article summarizes the existing literature on use of radiotherapy for node-positive prostate cancer, as well as the associated outcomes.


Subscribe to Genitourinary Cancers on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.